Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HT-001

Small molecule · Modulator

Phase 2 Most advanced trial
1 Registered trials

What is HT-001?

HT-001 is a topical gel with potential immunomodulatory activity, applied to the skin, scalp and nails. It is intended to inhibit the recruitment and activation of immune cells and the expression of inflammatory mediators triggered by EGFR signaling blockade. It is being studied for skin toxicity caused by EGFR inhibitor cancer therapy, including acneiform eruption, xerosis cutis and paronychia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Modulator
Pathways
EGFR signaling, inflammatory cytokine production, immune cell recruitment
Therapy area
Dermatology
In trials of
ICLR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05639933 Phase 2 Acneiform Eruption Due to Chemical Recruiting ICLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acneiform Eruption Due to ChemicalParonychiaXerosis Cutis

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.